 Connection
Ty Kiser to Anticoagulants
This is a "connection" page, showing publications Ty Kiser has written about Anticoagulants.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.055 |
|
|
|
-
Farrar JE, Trujillo TC, Mueller SW, Beltran L, Nguyen C, Hassell K, Kiser TH. Evaluation of a patient specific, targeted-intensity pharmacologic thromboprophylaxis protocol in hospitalized patients with COVID-19. J Thromb Thrombolysis. 2022 Feb; 53(2):446-453.
Score: 0.571
-
Van Matre ET, Reynolds PM, MacLaren R, Mueller SW, Wright GC, Moss M, Burnham EL, Ho PM, Vandivier RW, Kiser TH. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer. J Thromb Haemost. 2018 12; 16(12):2492-2500.
Score: 0.472
-
Beyer JT, Schoeppler KE, Zanotti G, Weiss GM, Mueller SW, MacLaren R, Fish DN, Kiser TH. Antithrombin Administration During Intravenous Heparin Anticoagulation in the Intensive Care Unit: A Single-Center Matched Retrospective Cohort Study. Clin Appl Thromb Hemost. 2018 Jan; 24(1):145-150.
Score: 0.406
-
Dager WE, Kiser TH. Systemic anticoagulation considerations in chronic kidney disease. Adv Chronic Kidney Dis. 2010 Sep; 17(5):420-7.
Score: 0.267
-
Mueller SW, MacLaren R, Fish DN, Kiser TH. Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy. Ann Pharmacother. 2009 Jul; 43(7):1360-5.
Score: 0.247
-
Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2008 Sep; 28(9):1115-24.
Score: 0.233
-
Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy. 2006 Apr; 26(4):452-60.
Score: 0.197
-
Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy. 2005 Dec; 25(12):1736-45.
Score: 0.192
-
Novak AR, Shakowski C, Trujillo TC, Wright GC, Mueller SW, Kiser TH. Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism. J Thromb Thrombolysis. 2022 Aug; 54(2):276-286.
Score: 0.151
-
Reynolds PM, Van Matre ET, Wright GC, McQueen RB, Burnham EL, Ho PJM, Moss M, Vandivier RW, Kiser TH. Evaluation of Prophylactic Heparin Dosage Strategies and Risk Factors for Venous Thromboembolism in the Critically Ill Patient. Pharmacotherapy. 2019 03; 39(3):232-241.
Score: 0.120
-
Beyer J, Trujillo T, Fisher S, Ko A, Lind SE, Kiser TH. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. Clin Appl Thromb Hemost. 2016 Jul; 22(5):423-8.
Score: 0.097
-
Kiser TH, MacLaren R, Fish DN, Hassell KL, Teitelbaum I. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy. 2010 Nov; 30(11):1117-26.
Score: 0.068
-
Bass ME, Kiser TH, Page RL, McIlvennan CK, Allen LA, Wright G, Shakowski C. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Thromb Thrombolysis. 2021 Aug; 52(2):517-522.
Score: 0.034
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|